HONG KONG, Mar 30, 2020 - (ACN Newswire) - Aptorum Group
Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical
company focused on the development of novel therapeutics to address
global unmet medical needs, today provides an update on the
Company's operations in light of the recent declaration of the
coronavirus outbreak as a pandemic declared by the World Health
Organisation on March 11, 2020.
Aptorum Group's operational plans continue to remain on track, and
in particular the recently announced updates on SACT-1 (targeting
Neuroblastoma) and ALS-4 (targeting Staphylococcus aureus) remain
on track for its pre-IND preparation work and will continue to
target for IND submission in the second half of 2020. With the
additional capital raised in February 2020, the Company is also on
track in expanding strategic initiatives including the discovery
and development pipeline such as the recently announced initiative
SACT-COV19 (targeting COVID-19 disease) and additional Smart-Act
platform projects being SACT-2 and SACT-3, which will be announced
in due course. The Company, together with the distributor, is also
focused on the distribution of the recently announced non-hormonal
based Dioscorea Opposita bioactive nutraceutical supplement
targeting woman's health during menopause or post-menopause cycles.
In light of the global coronavirus situation, the Company would
like to report that its day to day operations continue to proceed
as normal.
The management of the Company will also host its first quarter 2020
investor update conference call to discuss recent developments and
plans for the Company on Thursday, April 2, 2020. Aptorum Group
will also provide updates during the call on the progress of its
existing pipeline, including SACT-1 and ALS-4, and the latest
announced project targeting the coronavirus group including
COVID-19. A conference call will be held on Thursday, April 2, 2020
at 10:00am Hong Kong time (April 1, 2020 at 10:00pm EST) by the
executive management team. If you have any specific question(s) for
the Company and its projects, please email your question(s) to
investor.relations@aptorumgroup.com on or before 10:00pm EST
Tuesday, March 31, 2020.
To participate in the call, please dial +852 3018 8307 (for Hong
Kong callers) or 1-844-760 0770 (for US callers) using conference
ID number 6995532. The archived webcast will be available on the
Investors section of Aptorum Group's website
(http://ir.aptorumgroup.com/) approximately one hour after the call
has completed.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle unmet medical needs. Aptorum Group's current drug pipeline
include indications in orphan diseases, infectious diseases and
metabolic diseases and a number of which are targeted to enter
clinical trial phases in 2020. Aptorum Group also operates a
woman's health supplement business whose Dioscorea Opposita
Bioactive Nutraceutical Tablets are currently being
commercialized.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as "may," "should," "expects," "plans," "anticipates,"
"could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential," or "continue," or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company's
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group's Form 20-F and other filings that Aptorum Group may make
with the SEC in the future. As a result, the projections included
in such forward-looking statements are subject to change. Aptorum
Group assumes no obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
Contacts
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com
Source: Aptorum Group Limited
Copyright 2020 ACN Newswire . All rights reserved. |